24 completed, 10 terminated, 6 withdrawn, 3 recruiting. 23 Phase 3, 8 Phase 2, 6 Phase 1, 4 Phase 4, 3 Not applicable.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device) - Healthy | Phase 2 | Terminated | AMAG Pharmaceuticals, Inc. | 41 | 2021-10-13 | 2026-04-20 |
| Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer - Vaginal Atrophy, Postmenopausal Symptoms | Phase 2 | Terminated | University of Arkansas | 8 | 2021-06-07 | 2024-11-27 |
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension Aspirin 81mg - Pre-Eclampsia | Phase 4 | Unknown | Eastern Virginia Medical School | 60 | 2021-05-28 | 2021-06-28 |
| 17-OHPC in Pregnancy: IM vs SC Routes 17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose - Preterm Birth | Terminated | Steve N. Caritis, MD | 24 | 2020-06-16 | 2023-08-03 | |
| Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women Prasterone, Placebo - Recurrent Urinary Tract Infection, Postmenopause | Phase 3 | Withdrawn | Olivia Cardenas-Trowers, M.D. | 2020-05-01 | 2021-06-30 | |
| Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient Ferumoxytol, Saline, Ferrous sulfate tablets - Iron Deficiency Anemia | Phase 3 | Recruiting | Auerbach Hematology Oncology Associates P C | 104 | 2020-02-27 | 2025-10-03 |
| IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding Ferumoxytol, Ferrous Sulfate - Anemia, Iron Deficiency, Heavy Menstrual Bleeding | Phase 4 | Unknown | Thomas Jefferson University | 76 | 2020-02-14 | 2023-11-21 |
| Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder Bremelanotide, Placebo - Hypoactive Sexual Desire Disorder | Phase 4 | Completed | Imperial College Healthcare NHS Trust | 40 | 2019-10-07 | 2024-08-09 |
| A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects ferumoxytol, Iron sucrose - Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 75 | 2019-09-18 | 2026-04-17 |
| Intravenous (IV) Versus Oral Iron Treatment of Iron Deficiency Anemia in the Post-operative Bariatric Surgical Patient Ferumoxytol, Ferrous sulfate, Oral vitamin C - IDA in the Post-bariatric Surgical Patient | Not applicable | Withdrawn | Johns Hopkins University | 2019-08-01 | 2019-09-11 | |
| Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran Bremelanotide, Zofran, Placebo - Nausea | Phase 1 | Completed | AMAG Pharmaceuticals, Inc. | 228 | 2019-06-17 | 2022-04-04 |
| Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy Ferrous sulfate 325mg, Ferumoxytol - Iron Deficiency Anemia of Pregnancy | Phase 3 | Completed | University of Arizona | 124 | 2018-12-17 | 2022-09-07 |
| Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study Placebo Vaginal Insert, Prasterone 6.5 mg (0.50%) Vaginal Insert - Hypoactive Sexual Desire Disorder (HSDD) | Phase 3 | Withdrawn | EndoCeutics Inc. | 2018-11-13 | 2020-07-31 | |
| Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer Placebo, Prasterone (DHEA) - Vaginal Atrophy in Breast Cancer Patients | Phase 3 | Withdrawn | EndoCeutics Inc. | 2018-11-06 | 2020-07-31 | |
| A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Ferumoxytol, Iron sucrose - Chronic Kidney Disease; Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 129 | 2018-08-13 | 2026-04-17 |
| Improving Pregnancy Outcomes With Progesterone 17P, Placebo - Pre-term Birth, HIV-1-infection | Phase 3 | Completed | University of North Carolina, Chapel Hill | 800 | 2018-02-07 | 2021-07-22 |
| Counseling for Prematurity Using a Multimedia Education Tool Multimedia Information, Printed Handout - Premature Birth, Counseling | Not applicable | Completed | Medical College of Wisconsin | 76 | 2017-12-01 | 2019-02-27 |
| Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors Ferumoxytol, Magnetic Resonance Imaging - Brain Neoplasm | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2017-10-20 | 2021-11-10 | |
| Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia AMAG-423 (digoxin immune fab), Placebo - Severe Preeclampsia | Phase 2 / Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 58 | 2017-04-12 | 2026-05-22 |
| Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) - Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women | Phase 3 | Terminated | AMAG Pharmaceuticals, Inc. | 60 | 2016-10-07 | 2022-04-21 |
Showing 20 of 45. Sign in to see all of them.
Anemia, Iron-Deficiency (16) · Anemia (8) · Premature Birth (4) · Renal Insufficiency, Chronic (4) · Sexual Dysfunctions, Psychological (3) · Brain Neoplasms (2) · Pre-Eclampsia (2) · Anxiety Disorders (1) · Atrophic Vaginitis (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Diabetes Mellitus, Type 1 (1) · Esophageal Neoplasms (1) · Hypertension (1) · Iron Deficiencies (1)
Ferrosoferric Oxide (26) · Iron (7) · Ferric Oxide, Saccharated (5) · Dehydroepiandrosterone (4) · ferrous sulfate (4) · 17 alpha-Hydroxyprogesterone Caproate (3) · bremelanotide (3) · Ascorbic Acid (2) · ferrous fumarate (2) · ferryl iron (2) · 17-alpha-Hydroxyprogesterone (1) · Aspirin (1) · Erythropoietin (1) · Iron-Dextran Complex (1) · Magnetic Resonance Spectroscopy (1)
United States (38) · Canada (8) · Poland (8) · Hungary (7) · Latvia (4) · Lithuania (4) · United Kingdom (4) · India (3) · Spain (3) · Ukraine (3) · Czechia (2) · Germany (2) · Italy (2) · Russia (2) · South Africa (2)
Claude Labrie, M.D., Ph.D. (2) · Michael Auerbach, MD (2) · David F Archer, M.D. (1) · Edward A Neuwelt (1) · Edward A Neuwelt, MD (1) · Gloria Richard-Davis, MD (1) · Jeff Stringer, MD, FACOG (1) · Julie Krop, MD (1) · Kimberley E Steele, MD, Ph.D (1) · Mir A Basir, MD (1) · Neil Singla, MD (1) · Olivia Cardenas-Trowers, M.D. (1) · Philip E. Greilich, MD (1) · Richard A Jackson, M.D. (1)
PMID 22874106, PMID 10782451, PMID 18525001, PMID 18824288, PMID 19176796, PMID 21123946, PMID 23828252, PMID 24458078, PMID 25734980, PMID 26291918, PMID 26517756, PMID 26597311, PMID 26634942, PMID 26731686, PMID 26972555, PMID 28189361, PMID 28372549, PMID 28640161, PMID 29191450, PMID 30518682, PMID 30802204, PMID 30813934, PMID 31599840, PMID 31599847, PMID 31652479, PMID 33033885, PMID 33538638, PMID 34509197, PMID 35147466, PMID 36189794, PMID 36708966, PMID 36809187, PMID 37348816, PMID 37348817, PMID 37651553
2009 (1), R01HD087119 (1)